Recent Winners


+180%
PLX
Alert Price: $0.36
High Price: $1.01
Results: 180% in 40 Days
+157%
OREX
Alert Price: $1.81
High Price: $4.65
Results: 157% in 36 Days
+133%
CGIX
Alert Price: $1.50
High Price: $3.50
Results: 133% in 85 Days
+91%
GBT
Alert Price: $15.85
High Price: $30
Results: 91% in 41 Days
+90%
LPTH
Alert Price: $1.40
High Price: $2.66
Results: 90% in 69 Days
+87%
ARIA
Alert Price: $12.72
High Price: $23.75
Results: 87% in 20 Days
+72%
TRR
Alert Price: $10.10
High Price: $17.38
Results: 72% in 51 Days
+64%
MBLY
Alert Price: $37.68
High Price: $61.73
Results: 64% in 67 Days
+58%
AAOI
Alert Price: $28.22
High Price: $44.46
Results: 58% in 60 Days
+58%
XGTI
Alert Price: $1.47
High Price: $2.32
Results: 58% in 29 Days
+55%
EXAS
Alert Price: $15.10
High Price: $23.40
Results: 55% in 37 Days
+47%
CPRX
Alert Price: $1.20
High Price: $1.76
Results: 47% in 60 Days
+45%
PTLA
Alert Price: $25.06
High Price: $36.40
Results: 45% in 67 Days
+44%
VRTX
Alert Price: $79.39
High Price: $114.06
Results: 44% in 51 Days
+38%
EDIT
Alert Price: $18.24
High Price: $25.09
Results: 38% in 55 Days
+36%
CYNO
Alert Price: $48.25
High Price: $65.90
Results: 36% in 28 Days
+35%
NKTR
Alert Price: $13.75
High Price: $18.50
Results: 35% in 51 Days
+32%
EBS
Alert Price: $27.22
High Price: $35.88
Results: 32% in 6 Days
+31%
ATVI
Alert Price: $37.05
High Price: $48.42
Results: 31% in 68 Days
+27%
ILMN
Alert Price: $134.56
High Price: $171.52
Results: 27% in 55 Days
+27%
ICHR
Alert Price: $13.40
High Price: $17.04
Results: 27% in 22 Days
+27%
QRVO
Alert Price: $55.67
High Price: $70.64
Results: 27% in 73 Days
+25%
WILN
Alert Price: $1.58
High Price: $1.98
Results: 25% in 72 Days
+25%
BMA
Alert Price: $70.05
High Price: $87.41
Results: 25% in 61 Days
+23%
CNAT
Alert Price: $4.43
High Price: $5.45
Results: 23% in 3 Days
+23%
PEIX
Alert Price: $8.30
High Price: $10.25
Results: 23% in 12 Days
+21%
KATE
Alert Price: $15.40
High Price: $18.67
Results: 21% in 11 Days
+20%
REPH
Alert Price: $6.89
High Price: $8.25
Results: 20% in 11 Days
+20%
GNRT
Alert Price: $4.49
High Price: $5.37
Results: 20% in 62 Days
+20%
SN
Alert Price: $11.24
High Price: $13.46
Results: 20% in 15 Days
+20%
DXCM
Alert Price: $63.23
High Price: $76.06
Results: 20% in 68 Days

Past results are not indicative of future profits. This table is accurate, though not every trade is represented.

biotech

Trading Lessons

Mainstream Financial News

Archives

Hearing Takeover Rumors about Sarepta Therapeutics

April 18, 2017: Hearing vague takeover rumors circulating about Sarepta Therapeutics. The rumor is that Alexion could be interested in acquiring the company at around $55 per share. Could not find the source of the rumors.

February 14, 2017: Sarepta Therapeutic’s stock has formed a candle over candle reversal after Feuerstein said, “Sarepta Therapeutics is (Read More….)

Novartis AG Drama Builds As It Keeps JULIET Results Secret For Now

February 28, 2016: Novartis announced that the FDA has approved Afinitor for the treatment of some tumors. The FDA has approved everolimus (Afinitor) for the treatment of adult patients with progressive, well-differentiated non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin with unresectable, locally advanced or metastatic disease. The approval was based on demonstration of improvement in progression-free survival (PFS) in a multicenter, randomized (2:1), placebo-controlled trial of everolimus 10 mg orally once daily plus best supportive care (BSC) to placebo plus BSC. (Read More….)

CRISPR Therapeutics Announces European Patent for CRISPR/Cas Gene Editing

March 28, 2017: CRISPR Therapeutics reported that the European Patent Office (EPO) has announced its intention to grant a patent broadly covering CRISPR’s in-licensed gene editing technology. The claims are directed to the CRISPR/Cas9 single-guide gene editing system for uses in both non-cellular and cellular settings, including in cells from vertebrate animals such as human (Read More….)

Sells Editas Medicine For a 38% Win

March 4, 2017: Sell Editas Medicine for a 38% win in 55 days. Congratulations if you made money on the trade.

February 15, 2017: Editas Medicine confirms patent office decision favorable to Broad Institute in CRISPR Interference. Editas Medicine’s stock is up more than +27% on the news.

The U.S. Patent and Trademark Office (USPTO) (Read More….)

CRISPR’s Brave New World

Just a handful of technologies deserve to be called “game changers”—and CRISPR-Cas9, the new gene-editing tool, is one of them. Discovered just three years ago, CRISPR is sweeping through labs around the world and researchers are already using it to experiment on diseases like cancer and AIDS, engineer new sources of clean energy, and create (Read More….)